Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study

PURPOSE: Cabozantinib (XL184), a multi-targeted oral tyrosine kinase inhibitor with activity against MET, VEGFR2, AXL, and other tyrosine kinases, was assessed in a cohort of metastatic breast cancer (MBC) patients in a phase II randomized discontinuation trial (RDT). METHODS: Patients received 100 ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Tolaney, Sara M., Nechushtan, Hovav, Ron, Ilan-Gil, Schöffski, Patrick, Awada, Ahmad, Yasenchak, Chris A., Laird, A. Douglas, O’Keeffe, Bridget, Shapiro, Geoffrey I., Winer, Eric P.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2016
Assuntos:
Clinical Trial
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5065609/
https://ncbi.nlm.nih.gov/pubmed/27714541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-016-4001-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados